A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
16/01/2023at 10:06

Welcome to the new MedWatch

An uncompromising focus on quality journalism has made Watch Media a rising star in Nordic business journalism. A new design will strengthen the user experience on MedWatch and our other media.
Anders Heering, editor-in-chief, Watch Media | Photo: Philip Hoepner
by MedWatch

Dear Reader,

Independent, critical, and fair business journalism focused on substance. The ambition of our journalists is always the same – every day, we want to make you more knowledgeable about the industry in which you have a particular interest.

That’s why we usually spend all our energy on creating relevant content to prepare you for your workday in or about an industry. But we have now turned our attention to how we present our journalism.

Today, we launch a new design on MedWatch and across our English sites.

The goal of the design is to give our content breathing space with a more contemporary, journalistic expression, complete with a more readable font for all devices.

The goal of the design is to give our content breathing space with a more contemporary, journalistic expression, complete with a more readable font for all devices

MedWatch is, as all of our other media, a subscription service. That means we can concentrate on creating value for our subscribers instead of collecting clicks or disturbing users’ experience with intrusive advertising.

We’re sticking with a clean, comprehensible, and slightly conservative, design – a design that will make it easy and fast to get an overview of what’s new in the industry and to navigate our unique content – to the benefit our busy readers and advertisers alike.

We know changes will require some getting used to, but we hope our readers will become fond of our new design, which will be improved further over coming weeks and months. Indeed, we might never fully stop tinkering with it, as we are never done pushing the quality of our content.

We are honored and proud of what we have achieved with Watch Media, but we are far from the finish line. Not with MedWatch either. We seek to become better, and we would like your help.

Be it praise or criticism, tips or ideas – we are just one e-mail or call away. We are honestly interested in what’s on your mind.

Help us make MedWatch even stronger.

Enjoy your reading,

Anders Heering

Editor-In-Chief, Watch Media

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Viatris's headquaters in Pittsburgh, Pennsylvania, US | Foto: Viatris/PR.
Pharma & biotech

Novo Nordisk sues Viatris over copycat Wegovy

A market authorization application from US-based generics maker Viatris for a copy version of obesity treatment Wegovy breaches five of Novo Nordisk’s patents, claims the company in a lawsuit.
  • Novo Nordisk doubles obesity sales in 2022
  • New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst

For subscribers

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Foto: Stine Bidstrup
Pharma & biotech

Potential blockbuster submitted by Novo Nordisk for European approval

For subscribers

Further reading

Anders Hinsby (left), Thomas Kirkegaard Jensen, and Anders Vadsholt | Foto: Anne Bæk/Ritzau Scanpix
Pharma & biotech

Orphazyme trio founds new firm focused on neurology and rare diseases

Anders Hinsby, Anders Vadsholt, and Thomas Kirkegaard Jensen – all three key figures from now-defunct biotech company Orphazyme – have established a new company using experiences from the past.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk predicts wide range for 2023 sales growth

The Danish drugmaker has released its 2023 guidance with a sales growth expectation of 13–19%. (Updated)

For subscribers

Foto: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Latest news

  • Potential blockbuster submitted by Novo Nordisk for European approval – 13:51
  • Novo Nordisk sues Viatris over copycat Wegovy – 12:46
  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
See all

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Regulatory Affairs Professional

  • Application Manager

  • Commercial Director

  • Experienced Patent Counsel

See all jobs

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Sr. Director, Drug Safety Physician

  • Head of Regulatory Affairs Danmark

  • Lead Data Architect

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Regulatory Affairs Professional

  • Application Manager

  • Commercial Director

  • Experienced Patent Counsel

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge